Synthesis and antitumor activity of capecitabine derivatives

Xuedong Jia; Xiujun Liu; Jian Wang; Minghua Wang; Huiyuan Guo; Mingliang Liu

doi:10.1007/s40242-015-4282-4

Chemical Research in Chinese Universities ›› 2015, Vol. 31 ›› Issue (1) : 78 -83. DOI: 10.1007/s40242-015-4282-4

Article

Synthesis and antitumor activity of capecitabine derivatives

Author information +

History +

PDF

Abstract

A series of capecitabine derivatives with a Boc group at the N ⁴-position was synthesized and their in vitro antitumor activities against HepG2(liver hepatocellular carcinoma) were primarily evaluated. Some compounds were chosen for further evaluation of their in vivo efficacy on nude mice xenografted human hepatoma HepG2. The results showed that compounds 3 and 6 had considerable in vivo activity against HepG2, with tumor growth inhibition rates of 70% and 64% on day 21, respectively, and 56% and 55% on day 35, respectively, which are roughly comparable to capecitabine(74% and 59% on days 21 and 35, respectively).

Keywords

Capecitabine / Derivative / Antitumor activity

Cite this article

Download citation ▾

Xuedong Jia, Xiujun Liu, Jian Wang, Minghua Wang, Huiyuan Guo, Mingliang Liu. Synthesis and antitumor activity of capecitabine derivatives. Chemical Research in Chinese Universities, 2015, 31(1): 78-83 DOI:10.1007/s40242-015-4282-4

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Lv K, Wang L L, Liu M L, Zheng Z B, Li S. Med. Chem. Res., 2013, 22: 1723.

[2]	Ji H F, Chi B R, He D Y, Li C, Hu N N, Wang K, Sheng Y, Wang H Y, Jin N Y. Chem. Res. Chinese Universities, 2013, 29(2): 270.

[3]	Sanjay K S, Amrita J, Shiv K A, Rama M, Anand C B. Anticancer Agents Med. Chem., 2007, 7: 685.

[4]	Zhang J, Shan Y, Pan X, He L. Mini-Rev. Med. Chem., 2011, 11: 920.

[5]	Wang Y Y, Liu J Z, Yu X Y, Yang D Z, Zhang L N, Zhao G S. Chem. Res. Chinese Universities, 2013, 29(3): 454.

[6]	Helena A Y, Gregory J R. J. Natl. Compr. Canc. Netw., 2013, 11(2): 161.

[7]	Jin L L, Jin G Z. Chem. Res. Chinese Universities, 2012, 28(6): 971.

[8]	Almeidaa M Q, Hoff A O. Curr. Opin. Oncol., 2012, 24: 229.

[9]	Westin S N, Herzog T J, Coleman R L. New Drugs, 2013, 31: 213.

[10]	Guo S C, Zhao Y F, Li R D, Xie L J, Yang Y B, Gong P. Chem. Res. Chinese Universities, 2008, 24(1): 47.

[11]	Rich T A, Shepard R C, Mosley S T. J. Clin. Oncol., 2004, 22: 2214.

[12]	Chabner B A, Longo D. L., Cancer Chemotherapy and Biotherapy—Principles and Practice, 1996, Philadelphia: Lippincott-Raven 149.

[13]	Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, Miwa M, Ura M, Sawada N, Tahara H, Kuruma I, Horii I, Ishitsuka H. Bioorg. Med. Chem., 2000, 8: 1697.

[14]	Silverman R B. The Organic Chemistry of Drug Design and Drug Action, 1992, New York: Academic Press 19.

[15]	Lokich J J, Moore C L, Anderson N R. Cancer, 1996, 78: 294.

[16]	Ross P, Heron J, Cunnigham D. Eur. J. Cancer, 1996, 32: S13.

[17]	Ishitsuka H, Shimma N, Horii I. Discovery and Development of novel Anticancer Drug Capecitabinel, 1999, 119: 881.

[18]	Ninomiya Y, Miwa M, Eda H, Sahara H, Fujimoto K, Ishida M, Umeda I, Yokose K, Ishitsuka H. Jpn. J. Cancer Res., 1990, 81: 188.

[19]	Jhansi R V, Raghavendra K A, Nanda Kumar Y, Hema Kumar K, Jagadeeswarareddy K. Eur. J. Med. Chem., 2012, 54: 690.

[20]	Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J T, Bokesch H, Kenney S, Boyd M R. J. Natl. Cancer Inst., 1990, 82: 1107.

[21]	Furfine E S, Baker C T, Hale M R, Reynolds D J, Salisbury J A, Searle A D, Studenberg S D, Todd D, Tung R D, Spaltenstein A. Antimicrob. Agents Chemother., 2004, 48: 791.